PlainPill

Atomoxetine

Also known as Strattera

The short answer. Most people who report on Atomoxetine say it did not help (only 34% of 79 positive). It is most often used for focus: 71% of 45 reports say that improved. It is well studied — 152 meta-analyses on PubMed. The most common complaint is fatigue.

What users report
34%helped79 reports · medium confidence
27 helped18 mixed34 didn't help

From 137 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
152
meta-analyses
268
RCTs
2,252
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Atomoxetine does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 152 meta-analyses on PubMed ↗ · 268 randomized trials ↗

Lancet Psychiatry · 2018 · Meta-analysis / systematic review
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis

Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.

PubMed 30097390 ↗
J Am Acad Child Adolesc Psychiatry · 2025 · Meta-analysis / systematic review
Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life

Conclusion: In addition to being efficacious in reducing ADHD core symptom severity, both stimulant and nonstimulant medications are efficacious in improving QoL in people with ADHD, albeit with lower effect sizes. Future research should explore whether, and to what degree, combining pharmacological and nonpharmacological interventions is likely to further improve QoL in people with ADHD.

PubMed 38823477 ↗
Mol Autism · 2022 · Meta-analysis / systematic review
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis

Conclusion: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.

PubMed 35246237 ↗
Lancet Psychiatry · 2025 · Meta-analysis / systematic review
Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis

Conclusion: Stimulants and atomoxetine were the only interventions with evidence of beneficial effects in terms of reducing ADHD core symptoms in the short term, supported by both self-reported and clinician-reported ratings. However, atomoxetine was less acceptable than placebo. Medications for ADHD were not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated. The effects of non-pharmacological strategies were inconsistent across different raters. Our network meta-analysis represents the most comprehensive synthesis of available evide

PubMed 39701638 ↗
Registered clinical trials

224 human trials on ClinicalTrials.gov test Atomoxetine — 170 completed, 14 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER All atomoxetine-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the…”

Full label on DailyMed (NIH) ↗

FDA recalls

19 recalls of products named for Atomoxetine. Most recent:

  • 2026-05-27 · Class II: Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule. record ↗
  • 2025-02-26 · Class II: CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit. record ↗
  • 2015-04-29 · Class II: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

26,969 adverse-event reports mention Atomoxetine. Most often reported:

  • Drug ineffective · 2,955
  • Nausea · 2,250
  • Fatigue · 2,244
  • Headache · 1,844
  • Vomiting · 1,814
  • Off label use · 1,799

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Atomoxetine C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗

US government research funding (NIH)

NIH has funded 19 research projects with Atomoxetine in the title, $11,853,723 in total (2004–2026). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Atomoxetine ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

fatigue ×4nausea ×4insomnia ×4drowsiness ×3testicular pain ×2aggression ×2sexual dysfunction ×2erectile dysfunction ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“Helps focus / concentration immensely... Seems to improve my memory as well.”
HelpedRead the discussion ↗
“Atomoxetine made me way more impulsive and gave me sexual side effects right off the bat.”
MixedRead the discussion ↗
“Currently I am on Strattera and the side effects have subsided so I am only feeling the positives. A lot less stress and anxiety and ADHD is minimal.”
HelpedRead the discussion ↗
“I've tried the traditional ADHD meds like Strattera and Guanfacine, and they don't offer any improvement.”
Didn't helpRead the discussion ↗
Read more Atomoxetine reviews →
Top discussions (5)

Other options for focus

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate